Efficacy of adding midazolam to paracetamol in pain control of patients with a primary headache: A randomized, clinical trial study

Mahin Amini-Parikhani1, Amir Ghaffarazad2, Hassan Soleimanpour3, Haniyeh Ebrahimi-Bakhtavar2, Farzad Rahmani4

1Student Research Committee, Tabriz University of Medical Sciences, 2Emergency Medicine Research Team, Tabriz University of Medical Sciences Tabriz, East Azerbaijan, I. R, 3Cardiovascular Research Center, Tabriz University of Medical Sciences, 4Emergency Medicine Department, Tabriz University of Medical Sciences, Tabriz, Iran

*Corresponding Author

Abstract:
OBJECTIVES: This study aimed to determine the effect of adding intravenous midazolam to paracetamol in the treatment of patients with primary headache referring to the emergency department.

METHODS: In a randomized clinical trial, 120 patients (18–65 years old) with primary headache referring to the emergency department were enrolled. Patients were divided into two groups (case: paracetamol + midazolam and control: paracetamol + placebo), and the treatment was administered based on the treatment group. The severity of pain (according to the initial Visual Analog Scale) and at different times after the treatment onset (15, 30, and 60 min) and the degree of satisfaction with the treatment were compared in two groups of patients.

RESULTS: There were no statistically difference between the two groups about the median of pain severity at the time of 0 min (case: 8 vs. control: 8), 15 min (case: 6 vs. control: 6), and 30 min (case: 4 vs. control: 4) with \(P > 0.05\). Headache severity at 60 min after the treatment onset in the case group (median: 1) was less than that of the control group (median: 3). There was also a statistically significant difference in the median of patient satisfaction in the case group (case: 9 and control: 7 with \(P < 0.001\)) and satisfaction in the case group was higher.

CONCLUSIONS: Based on our primary and secondary outcomes and the results of the study, we conclude that adding intravenous midazolam to paracetamol do not improve the therapeutic response ratio over time, but the effect of this intervention appeared after 1 h.

Keywords: Emergency ward, headache, midazolam, migraine, paracetamol, tension headache

Introduction

Headache is one of the common reasons that people are referred to emergency wards.\([1]\) Most of the referrals include primary headaches, of which tension headaches and migraines are more common.\([5]\) Tension-type headache (TTH) is the most common form of primary headache and is multifactorial.\([3]\) Migraine headache is more common in women than in men.\([4]\) Psychological stress plays a major role in causing a headache. There is a relationship between stress and headache. How stress causes a headache is often not understood.\([5]\) Stress is a

Box-ED

What is already known on the study topic?
Primary headache is one of the common reasons that people are referred to emergency wards. There is a relationship between the stress intensity and headache frequency. Propofol, a sedative agent with similar pharmacological properties to midazolam, is shown to be effective in resistant migraine headaches.

What is the importance of the study for readers?
Addition of an anxiolytic agent to the standard primary headache treatment is unknown

How is this study structured?
This is a double-blind, randomized, clinical trial with 120 participants

What does this study tell us?
Addition of intravenous midazolam to paracetamol does not improve the therapeutic response ratio over time.

Methods

Trial design
This was a double-blind, randomized, clinical trial study conducted in the two emergency departments (EDs) in a large city affiliated to the University of Medical Sciences during a 12-month period (March 2017–2018). The inclusion criteria included the patients over the age of 18 years suffering from primary headache (migraine and tension) referred to the ED. The exclusion criteria included sensitivity to the study drugs, disorder in neurological examination, and secondary headaches, vomiting, pregnancy, disturbance of consciousness, liver failure, lactation, renal failure, mental disorder, no cooperation from the patient, receiving another drug during 6 h before referral to the emergency department, and unwillingness to participate in the research.

Sample size
In order to determine the sample size, initial information was obtained from the study of Faridaalaee et al.[12] Considering a confidence coefficient of 0.95 and an 80% power with using G*Power, Heinrich Heine Universität Düsseldorf, Germany, the minimum sample size with a clinical significance margin of 30% in the mean, 49 samples were calculated for each group. Given a 20% dropout rate, the sample size was increased to 60 in each group. The total sample size was thus 120.

Participants
We included 120 patients with primary headache to the study. Primary diagnostic criteria were based on the International Classification of Headache Disorders-II (ICHD-II).[17] We described the all ethical aspects of our study and medicines to the patients. Demographic data and type of headache were recorded based on the ICHD-II criteria and emergency physician opinions who were faculty member of the university and attended in the ED. The primary severity of headache patients was based on the Visual Analog Scale (VAS).

Randomization
Patients were divided into two-person blocks based on the Random Allocation Software, and then, the two groups of treatment case (paracetamol plus midazolam) and control (paracetamol plus placebo) were defined in the software. The randomization was done based on the results. The analysis strategy was intention to treat. Figure 1 shows a flow chart of patients in the study.

Blinding
For blinding, syringes-containing diluted midazolam or distilled water (syringes numbered 1 and 2) was prepared by the project executive. Neither the patients nor the treatment staff knew the contents of the syringes.

Midazolam is in the category of benzodiazepine drugs, and its effect is short and is used for sedation and short-acting anxiolytic.[14] Midazolam and propofol are used for sedation in the Intensive Care Unit. Propofol is similar to midazolam in terms of its pharmacologic profile, and studies have shown a similar efficacy and safety for both drugs in relaxing patients, but midazolam is less expensive than propofol.[15] Soleimanpour et al., in comparing the effect of intravenous dexamethasone and intravenous propofol in the treatment of patients with resistant migraine headache, showed that intravenous propofol is an effective and safe drug in the treatment of these patients.[16]

Considering the fact that one of the factors exacerbating migraine headaches and TTH is stress and anxiety based on previous studies, this study examines the effect of adding midazolam with a sedative dose to paracetamol to treat the patients with primary headache.
Intervention
The primary outcome variable was the control of pain in patients, and the secondary variable was their satisfaction. Paracetamol Ampoules© (Apotel, 1 g, 6.7 cc, cobel darou, Tehran, IR Iran) was dissolved in 100 ml of normal saline serum and infused into all patients within 10 min. The dose of acetaminophen was calculated at 15 mg/kg (not over than 1 g). Midazolam ampoule (1 cc, 5 mg, Darou Pakhsh, Tehran, IR Iran) at a relaxation dose of 0.02 mg/kg was intravenously and slowly injected to the patients in the treatment group at the onset of paracetamol administration. Placebo was 2 cc normal saline serum. All medicines were administered intravenously by an expert emergency nurse under the supervision of the researcher.

In two groups of the study, during administering the medicines, the researcher was at the bedside of the patient and monitored him/her. Fortunately, no special event occurred during the study, but the oxygen and devices that used to maintain the airway and breathing were in the bedside of patients. Furthermore, we prepared metoclopramide and opiate in resistant cases, but we never used them.

Outcome
The primary outcome variable was pain reduction across the time, and the secondary outcome variable was patient satisfaction about the treatment. The severity of pain in patients was recorded with the VAS at 15, 30, and 60 min after injection. The success of treatment and definitive pain control (i.e., pain intensity <3) were defined by the VAS criteria. Patient satisfaction at the end of the treatment period was recorded in the ED using the VAS criteria, where a score of 10 represents the highest satisfaction and 1 the lowest satisfaction. We use continuous numeric type of this scale in our study. One hour after administration the medicines, we did not observe the failure of treatment based on our treatment goals.

Statistical methods
All the data were analyzed using the SPSS software version 22.0 (Chicago). Descriptive statistical methods (mean ± standard deviation) of frequency and percentage and median were used for the statistical analysis of the obtained data. Normal distribution of the data was examined using the Kolmogorov–Smirnov test. A Chi-square test was used to compare the qualitative data in both groups. Because of the distribution of pain scores in different time and satisfaction levels were abnormal based on the Kolmogorov–Smirnov test (P < 0.05), for analysis of these data we used Mann–Whitney U-test. In all cases, P < 0.05 was statistically significant.
Results

One hundred and twenty patients participated in this study. The sex distribution in this study was 37 men (30.8%) and 83 women (69.2%). The mean and standard deviation of total patients’ age was 36.26 ± 12.06.

Table 1 shows a comparison of demographic variables and severity of headache between the two groups. As shown in Table 1, there was no statistically significant difference between the two groups in terms of demographic variables and primary severity of headache.

Table 2 shows the effect of treatment on the severity of headache at different times after treatment onset and the satisfaction of patients in the two groups. There was a statistically significant difference between headache severity at 60 min after treatment onset and satisfaction in two headache groups (median of case group: 1 and median of control group: 3, P < 0.001) and satisfaction was higher in the paracetamol + midazolam group (median of case group: 9 and median of control group: 7; P < 0.001).

In order to evaluate the response ratio to treatment of headache in patients over time, a Friedman test was used. The reduction ratio (reduction in the severity of headache to treatment) in the two groups of the study was statistically significant (P < 0.001); thus, there is not any difference between two group based on the response ratio to the treatment.

Discussion

In our study, we evaluated the adjuvant therapy of midazolam adding to paracetamol in the treatment of tension type and migraine headaches. Based on our results, the adding of midazolam to paracetamol leads to better treatment of primary headaches and improves the patient satisfaction.

The headache is a common complaint and accounts for nearly 5 million visits in the USA per year. Headaches are divided into two groups of primary and secondary headaches. Primary headaches include cluster, migraine, and tension, which seem to constitute the majority of emergency headaches.[18] However, most patients who come to the ED with headache often have a benign headache, but no serious and life-threatening causes should be ignored.[19] An important challenge for an emergency physician is to identify a headache that is a sign of a serious and life-threatening illness.[18]

The treatment medicines used for migraine headaches in the emergency wards include intravenous fluids, antidopaminergic, butyrophenones, metoclopramide, triptans, dihydroergotamine, nonsteroidal anti-inflammatory drug (NSAID), chlorpromazine, and metoclopramide, and for tension headaches include NSAID; chlorpromazine and metoclopramide.[11] For cluster headache, oxygen, subcutaneous sumatriptan, dopamine antagonists, and sometimes, corticosteroids are also used.[15] Opiate use is not recommended as a first-line treatment due to complications and prolonged stays in the emergency ward.[20]

Friedman et al. examined the effect of adding intravenous diphenhydramine to metoclopramide as an adjunct therapy in migraine treatment, and finally, concluded that diphenhydramine did not improve the outcome of migraine patients.[21]
Soleimanpour et al. examined the effect of intravenous dexamethasone compared with propofol in reducing the pain of migraine headache patients. Pain relief was significantly more effective after propofol treatment, and Soleimanpour et al. concluded that propofol is an effective and safe intravenous medicine for patients with migraine referred to the emergency ward.[16] In a study by Faridaalaee et al. on comparing the effect of paracetamol with metoclopramide on the treatment of primary headaches in the emergency ward, it has been concluded that the effect of metoclopramide on the treatment of primary headaches is less than paracetamol.[12]

Studies show that stress can trigger headaches, and stress management is effective in managing headaches and providing appropriate therapeutic responses.[23] It has been reported that stress management with nonpharmacological methods such as lifestyle improvement and yoga in treating patients with migraine headaches could be effective.[23]

In the present study, there was no statistically significant difference between the two groups in terms of intensity of pain in the first minutes, 15 and 30 min after treatment onset, but the pain intensity in the paracetamol + midazolam group was less than the paracetamol + placebo group at 60 min after the treatment onset and patient satisfaction was higher in the paracetamol + midazolam group as well.

Limitations
Among the limitations of the study were no long-term follow-up of patients and a small sample size. We did not register the vital sign, comorbidities, and other variables of patients, and also we did not count the number of secondary headaches that we excluded from the study. Another limitation of our study was that we did not check the stress levels of patients before intervention. In considering midazolam as a new treatment for headache, treatment refusal by patients was another limitation of the study.

Conclusions
Based on our primary and secondary outcomes and the results of the study, we conclude that adding intravenous midazolam as a sedative agent to intravenous paracetamol do not improve the therapeutic response ratio over time, but when we added midazolam to paracetamol for the treatment of primary headache, the effect of this intervention appeared after 1 h, and there was no difference in treatment efficacy of adding midazolam between the two treatment groups before that. Furthermore, the patient satisfaction was significantly higher in apotel + midazolam group.

Further studies with larger sample sizes and long-term follow-up of patients for relapse or long-term satisfaction are recommended. It is also recommended that the effect of adding oral benzodiazepine as a prophylactic agent to routine treatment in patients with recurrent attacks of primary headache or chronic headache be studied, also it is recommended that in future studies the stress level of patients will evaluated.

Acknowledgments
The authors are grateful to all participated in the study. This article was written based on dataset of M.A. thesis entitled “The Effect of Adding Intravenous Midazolam to Apotel® in the treatment of patients with primary headache referred to the emergency department,” registered in our University of Medical Sciences (No: 94/1-5/19 January 02, 2016).

Funding
None declared.

Author contribution statement
All authors have read and approved the manuscript. Haniyeh Ebnaehimi-Bakhtavár conceived and designed the experiments, Mahin Amini-Parikhani performed the experiments, Amir Ghaffarzad analyzed and interpreted the data, Hassan Soleimanpour contributed reagents, materials, analysis tools or data, and Farzad Rahmani wrote the paper.

Conflicts of interest
None declared.

Ethical Approval
This project was approved by the Ethics Committee of Tabriz University of Medical Sciences with the code IR.TBZMED.REC.1395.325 on 04.07.2016. IRCT (Iranian Registry of Clinical Trials) code of this study is IRCT2016013112592N3.

References
Amini-Parikhani, et al.: Adjuvant therapy with midazolam in primary headache